Key Takeaways
- Federal regulators sent ImmunityBio a warning letter concerning a television advertisement and podcast featuring misleading statements about ANKTIVA
- The marketing content falsely implied ANKTIVA was effective against all cancer types — the drug has authorization solely for a narrow bladder cancer indication combined with BCG treatment
- The FDA specifically named company CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong in connection with the violations
- ImmunityBio has now received three regulatory communications from the FDA regarding promotional misconduct, with prior notices sent in September 2025 and January 2026
- ImmunityBio must submit a corrective action plan within 15 business days or potentially face enforcement proceedings
Shares of ImmunityBio experienced a significant decline on Tuesday following the FDA’s announcement that a television commercial and podcast episode contained illegal misrepresentations about the approved indications for ANKTIVA, representing the third time regulators have contacted the firm about promotional violations.
The warning letter from the FDA’s Office of Prescription Drug Promotion targeted a television spot and a podcast episode titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” Regulators concluded that both materials breached federal regulations.
The fundamental problem centered on overreach. ANKTIVA has regulatory approval for a single, narrowly defined application: the treatment of adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, whether accompanied by papillary tumors or not, when delivered intravesically in combination with BCG therapy.
The advertising content significantly exceeded those boundaries. The materials implied ANKTIVA possessed the capability to “treat all cancers,” could serve as a preventive measure for individuals exposed to radiation, and functioned as a standalone single-dose therapy. Not one of these assertions has been validated by clinical evidence or received FDA approval.
Both Chief Executive Officer Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong were featured in the promotional content and were explicitly identified in the regulatory warning.
According to the FDA, the materials constituted misbranding of ANKTIVA and rendered the drug’s commercial distribution in violation of the Federal Food, Drug, and Cosmetic Act.
History of Regulatory Issues
This represents far from the initial occasion that ImmunityBio has attracted regulatory scrutiny for such violations. The agency had already dispatched untitled letters during September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional deficiencies.
Tuesday’s correspondence constitutes the third regulatory communication — and represents the most severe action yet. A formal FDA warning letter carries substantially greater regulatory implications than an untitled letter and demonstrates the agency’s growing apprehension.
Regulators additionally faulted ImmunityBio for inadequate presentation of risk data in the promotional materials and for excluding essential information regarding the drug’s authorized indication.
The podcast episode also violated a distinct regulatory obligation: it was never submitted to the FDA when originally released, as required by law.
Investor Response
IBRX shares declined approximately 15% to 21% throughout Tuesday’s trading session, with certain reports indicating the stock tumbled as much as 21% during morning hours.
ImmunityBio has been given 15 business days to provide the FDA with a written response detailing its remediation strategy for addressing the violations.
The biotechnology firm must also develop and distribute corrective communications specifically directed toward audiences who were exposed to the misleading promotional content.
The FDA cautioned that inadequate corrective measures could trigger legal enforcement actions.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
